Navigation Links
Fluidigm Due Diligence: Company SWOT Analysis and Market Opportunity 2012
Date:3/11/2013

DUBLIN, March 11, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Fluidigm Due Diligence: Company SWOT Analysis and Market Opportunity" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

In this report, we review Fluidigm's historical financial performance, and forecast Fluidigm's product revenues (2012E-2015F) by platform (BioMark / BioMark HD, EP1, Access array, C1 single cell AutoPrep system [to be launched] and TOPAZ). Overall, we believe the company will grow at >25% p.a. until 2015 and reach revenues in excess of $100M. The majority of this growth is expected to be driven by continued placement of BioMark systems, especially for single-cell analysis. By the end of 2011, the company reported that >80 BioMark systems were being used for single-cell analysis. We expect this number to grow to 250-300 instruments by 2015.

In addition, this report provides an overview of the genomics and molecular diagnostics (MDx) spaces in which Fluidigm participates. We review the market growth and trends of both genomics and MDx by technology. The WW genomics market was estimated at -$6.8B in 2011, and forecasted to grow at -6% p.a. Fluidigm focuses on sub-segments of this market, at a specific throughput and plex-level. In addition, Fluidigm addresses three segments within this market: NGS sample preparation, single cell genomics and dPCR. We estimate the current (2011) and future (2015) market size for each of these niche segments.

We also provide an overview of the competitive landscape, with a key focus on dPCR, for which we provide a profile of 7 key competitors.

This report is based on an extensive review of Fluidigm's filings, publications and earning calls. In addition, we supplemented our analysis with an interview campaign of -18 users and non-users of various Fluidigm platforms. This information is compiled into a SWOT analysis presented at the end of the report.


Key Topics Covered:

Products and key applications

Customer types and installed base

Past and current revenues

Forecasted product revenues

Market opportunity

Competition

Partnerships and alliances

Fluidigm's SWOT analysis

IP Position

Appendix



For more information visit http://www.researchandmarkets.com/research/kbtd6q/fluidigm_due

Research and Markets
Laura Wood , Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +1-353-1-481-1716
Sector: Company Reports


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accordant Health Services, a CVS Caremark Company, Receives URAC Case Management Accreditation
2. Endo Health Solutions to Present at the Cowen and Company 33rd Annual Health Care Conference
3. Auxilium Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Healthcare Conference
4. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
5. Amgen To Present At The Cowen and Company 33rd Annual Health Care Conference
6. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
7. PrimerLife.com, a Skolkovo Participant Company, Celebrates Anniversary of DNA Discovery with Launch of New Social Network
8. Collegium Pharmaceuticals CEO to Present at the Cowen & Company 33rd Annual Health Care Conference in Boston on March 6, 2013
9. Vanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
10. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
11. Neurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):